GT Biopharma to Present at SITC 2026 Annual Meeting
The company will discuss new research on sensitizing pancreatic cancer to NK cell immunotherapy on November 6, 2026.
Updated on Oct. 26, 2026 in Cancer
Live Poll
Do you believe recent advancements in targeted cancer therapy will improve treatment success rates in your area?
GT Biopharma will deliver an oral presentation on its TriKE technology at the Society for Immunotherapy of Cancer 2026 Annual Meeting. The presentation is scheduled for November 6, 2026, as part of a session on combination therapies.
Why it matters
The research focuses on the potential to sensitize pancreatic cancer to NK cell immunotherapy by inhibiting the KRAS oncoprotein. This presentation highlights ongoing developments in specialized cancer treatments involving the company's licensed technology.
The oral presentation, identified by abstract number 655, is scheduled to take place during Session 106a. This session runs from 1:45 PM to 3:25 PM, with the specific presentation occurring between 3:05 PM and 3:20 PM Mountain Time.
The players
GT Biopharma
This biotechnology company holds an exclusive worldwide license for TriKE technology from the University of Minnesota.
Society for Immunotherapy of Cancer
This professional organization hosts the annual meeting focused on cancer immunology research and advancements.
Paarth Dodhiawala
He is a researcher at the University of Minnesota Medical School and the designated presenter for the session.
University of Minnesota Medical School
This academic institution performs medical research and holds the original technology patents licensed to GT Biopharma.
The details
Paarth Dodhiawala of the University of Minnesota Medical School will present the research titled Inhibition of the KRAS oncoprotein sensitizes pancreatic cancer to NK cell immunotherapy. The event will be held in the North Building at the convention center, specifically on the 300 Level in Halls BC.
Timeline
The SITC 2026 Annual Meeting begins on November 4, 2026.
The oral presentation occurs on November 6, 2026.
The SITC 2026 Annual Meeting ends on November 8, 2026.
The Big Picture
This research presentation builds upon the development of the TriKE technology platform in cancer immunotherapy. The study marks an advancement in exploring how specific protein inhibition can be integrated into existing combination therapy frameworks.
This development represents a step in scientific research that may eventually influence future treatment options for pancreatic cancer patients. While currently at the presentation stage, these findings contribute to the ongoing evolution of immunotherapy standards.
The takeaway
This session highlights how specific molecular targets like KRAS are being investigated to improve the effectiveness of immune-based cancer therapies. Researchers and clinicians can look to these findings as an indication of how combination strategies are evolving in the laboratory.
Further reading
For more background on current oncology advancements, visit the Cancer section.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe recent advancements in targeted cancer therapy will improve treatment success rates in your area?
